ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of some unusual options trading on Thursday. Stock investors bought 8,015 call options on the stock. This is an increase of 36% compared to the average daily volume of 5,894 call options.
ImmunityBio Trading Down 3.3 %
NASDAQ:IBRX traded down $0.10 on Friday, hitting $2.94. The company's stock had a trading volume of 11,795,251 shares, compared to its average volume of 6,903,445. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The firm has a market capitalization of $2.05 billion, a P/E ratio of -3.20 and a beta of 0.86. The stock has a fifty day moving average of $3.74 and a two-hundred day moving average of $4.25.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. State Street Corp boosted its position in ImmunityBio by 10.1% during the third quarter. State Street Corp now owns 8,654,460 shares of the company's stock worth $32,195,000 after purchasing an additional 790,408 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of ImmunityBio by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company's stock worth $4,709,000 after buying an additional 29,665 shares during the last quarter. Barclays PLC boosted its holdings in shares of ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock worth $1,344,000 after buying an additional 202,248 shares during the period. Rhumbline Advisers grew its stake in ImmunityBio by 13.3% in the 2nd quarter. Rhumbline Advisers now owns 211,677 shares of the company's stock valued at $1,338,000 after buying an additional 24,802 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in ImmunityBio by 64.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 133,966 shares of the company's stock valued at $498,000 after acquiring an additional 52,716 shares during the period. 8.58% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd. D. Boral Capital restated a "buy" rating and set a $30.00 target price on shares of ImmunityBio in a report on Thursday. Finally, BTIG Research started coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a "buy" rating and a $6.00 price target on the stock.
Read Our Latest Report on ImmunityBio
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
